SCHEMBL4891620

SCHEMBL4891620

CC(=O)/C(=C/c1ccc(Cl)c(Cl)c1)C(=O)NCCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
HTT P42858 1/20 0.57
PLAAT5 Q96KN8 10/20 0.55
PLAAT4 Q9UL19 10/20 0.55
PLAAT3 P53816 9/20 0.55
PLAAT2 Q9NWW9 9/20 0.55
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
HPGD P15428 3/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 1/20 0.47
RGS12 O14924 1/20 0.47
GMNN O75496 1/20 0.47
EGFR P00533 1/20 0.47
ERBB2 P04626 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4498599 1.00 LMNA (0.57) LMNAHTTPLAAT5PLAAT4PLAAT3
SCHEMBL4491589 0.93 LMNA (0.49) LMNAHTTPLAAT5PLAAT4PLAAT3
SCHEMBL4889438 0.93 LMNA (0.49) LMNAHTTPLAAT5PLAAT4PLAAT3
SCHEMBL4488945 0.92 EGFR (0.50) LMNAHTTPLAAT5PLAAT4PLAAT3
SCHEMBL4899806 0.92 EGFR (0.50) LMNAHTTPLAAT5PLAAT4PLAAT3
SCHEMBL4504410 0.87 RAB9A (0.45) LMNAHTTPLAAT5PLAAT4PLAAT3
SCHEMBL4899673 0.87 RAB9A (0.45) LMNAHTTPLAAT5PLAAT4PLAAT3
SCHEMBL4503862 0.84 MTNR1A (0.49) MEN1KMT2A
SCHEMBL4900661 0.84 MTNR1A (0.49) MEN1KMT2A
SCHEMBL4503995 0.82 APOBEC3A (0.54) LMNAHTTPLAAT5PLAAT4PLAAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070903-A1 NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070903-A1 NEW PYRIMIDINE DERIVATIVES AND NEW PYRIDINE DERIVATIVES P2RY10, CACNA1B, CACNA1E LMNA 3830/4885HTT 3802/4885PLAAT5 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.